Towa Pharmaceutical Co., Ltd. (TSE: 4553)
Health Care · Pharmaceuticals · JP
¥3,895.00
+2.64% today · +28.1% 1Y
Towa Pharmaceutical Co., Ltd. (TSE: 4553) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.21B and employs 4,923 people.
Over the last twelve months the share price has gained 28.1%, trading between 2.76K and 4.49K.
Tweenvest scores Towa Pharmaceutical Co., Ltd. across four factors: quality 67/100, value 64/100, growth 64/100, dividend 52/100. Its strongest factor is quality.
4553 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.21B
- Revenue (TTM)
- $1.72B
- P/E
- 23.19
- EPS
- 167.95
- Dividend yield
- 2.18%
- Beta (5Y)
- -0.09
- 52-week high
- ¥4,490.00
- 52-week low
- ¥2,764.00
- Avg volume (3M)
- —
- Shares outstanding
- 49.23M
- Employees
- 4,923
- Next earnings
- —
About Towa Pharmaceutical Co., Ltd.
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
- ISIN
- JP3623150004
- Founded
- 1951
- Listed since
- Apr 5, 2004
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.